Seminars in Oncology
Volume 29, Issue 4 , Pages 361-369 , August 2002

The revised American Joint Committee on Cancer staging system for melanoma

References 

  1. Greenlee R, Murray T, Bolden S, et al.  Cancer statistics. CA Cancer J Clin. 2000;50:7–33
  2. In:  Fleming ID,  Cooper JS,  Henson DE, et al. editor. AJCC Cancer Staging Manual. Philadelphia, PA: Lippincott-Raven; 1997;
  3. Buzaid A, Ross M, Balch C. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of new staging system. J Clin Oncol. 1997;15:1039–1051
  4. Balch C, Buzaid A, Atkins M, et al.  The new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000;88:1484–1491
  5. Balch C, Soong S-J, Gershenwald J, et al.  Prognostic factors analysis of 17,600 melanoma patients. Validation of the new AJCC melanoma staging system. J Clin Oncol. 2001;19:3622–3634
  6. Balch C, Buzaid A, Soong S-J, et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648
  7. Corona R, Mele A, Amini M, et al.  Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol. 1996;14:18–23
  8. Lock-Anderson J, Hou-Jensen K, Hansen J, et al.  Observer variation in histological diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol. 1995;14:1218–1223
  9. Heenan P, Matz L, Blackwell J, et al.  Inter-observer variation between pathologists in the classification of cutaneous malignant melanoma in western Australia. Histopathology. 1984;8:717–729
  10. Larsen T, Little J, Orell S, et al.  International pathologists congruence survey on quantitation of melignant melanoma. Pathology. 1980;12:245–253
  11. Stadelmann W, Rapaport D, Soong S-J, et al.  Prognostic clinical and pathologic features. In:  Balch CM,  Houghton AN,  Sober AJ, et al. editor. Cutaneous Melanoma. St Louis, MO: Quality Medical Publishing; 1998;p. 11–35
  12. Balch C, Wilkerson J, Murad T, et al.  The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980;45:3012–3017
  13. Kim S, Garcia C, Rodriguez J, et al.  Prognosis of thick cutaneous melanoma. J Am Coll Surg. 1999;188:241–247
  14. Keilholz U, Conradt C, Legha S, et al.  Results of Interleukin-2 based treatment in advanced melanoma: A case record-based analysis of 631 patients. J Clin Oncol. 1998;16:2921–2929
  15. Eton O, Legha S, Moon T, et al.  Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol. 1998;16:1103–1111
  16. Balch C, Soong S, Murad T. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 patients with distant metastases (stage III). J Clin Oncol. 1983;1:126–134
  17. Barth A, Wanek L, Morton D. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193–201
  18. Brand C, Ellwanger U, Stroebel W, et al.  Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer. 1997;79:2345–2353
  19. Finck S, Giuliano A, Morton D. LDH and melanoma. Cancer. 1983;51:840–843
  20. Sirott M, Bajorin D, Wong G, et al.  Prognostic factors in patients with metastatic malignant melanoma. Cancer. 1993;72:3091–3098
  21. Deichmann M, Benner A, Block M. S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999;17:1891–1896
  22. Busam K. Lack of relevant information for tumor staging in pathology reports of primary cutaneous melanoma. Am J Clin Pathol. 2001;115:743–746
  23. Morton DL. Lymphatic mapping and sentinel lymphadenectomy for melanoma: Past, present, and future. Ann Surg Oncol. 2001;8(suppl 9):22S–28S
  24. Monzon J, Liu L, Brill H, et al.  CDKN2A mutations in multiple primary melanomas. N Engl J Med. 1998;338:879–887
  25. Hoon D, Wang Y, Dale P, et al.  Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol. 1995;13:2109–2116
  26. Tyler D, Onaitis M, Kherani A, et al.  Positron emission tomography scanning in malignant melanoma: Clinical utility in patients with stage III disease. Cancer. 2000;89:1019–1025
  27. Gown A, Vogel A, Hoak D, et al.  Monoclonal antibodies specific for melanoma. Am J Pathol. 1986;123:195–203
  28. Kelley M, Jones R, Gupta R, et al.  Tumor associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma. Cancer. 1998;83:1355–1361
  29. Li W, Shivers S, Lin J, et al.  Clinical relevance of molecular staging for melanoma: Comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg. 2000;231:795–803
  30. King R, Weilbaecher K, McGill G, et al.  Microphthalmia transcription factor. A sensitive and specific melanocyte marker for melanoma diagnosis. Am J Pathol. 1999;155:731–738

☆ Address reprint requests to John A. Thompson, MD, Seattle Cancer Care Alliance, 825 Eastlake Ave E, Mailstop G3-200, Seattle, WA 98109-1023.

PII: S0093-7754(02)50266-9

doi: 10.1053/sonc.2002.34115

Seminars in Oncology
Volume 29, Issue 4 , Pages 361-369 , August 2002

Article Tools

* Image Usage & Resolution